MedWatch

Analyst: Zegalogue launch should be "plug and play" for Novo Nordisk

Novo Nordisk’s well-oiled machine has good synergies with Zealand Pharma’s rescue pen, Zegalogue, says a Sydbank analyst, predicting that the product’s year-end revenues will grow due to the deal.

Novo Nordisk has purchased the rights to Zealand Pharma's rescue pen, Zegalogue | Photo: Novo Nordisk / PR

The sales and marketing muscles behind rescue pen Zegalogue (dasiclugon) will be beefed up by Novo Nordisk taking over the global marketing rights from Zealand Pharma, assesses Sydbank analyst Søren Løntoft Hansen.

According to the analyst, the Danish giant’s well-oiled machine combined with Zegalogue’s good fit within the portfolio should make for a ”plug and play” launch for Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs